🇺🇸 FDA
Pipeline program

forodesine hydrochloride (BCX-1777)

BCX1777-Bi-04-106

Phase 2 small_molecule completed

Quick answer

forodesine hydrochloride (BCX-1777) for B-cell Acute Lymphoblastic Leukemia is a Phase 2 program (small_molecule) at BIOCRYST PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
BIOCRYST PHARMACEUTICALS INC
Indication
B-cell Acute Lymphoblastic Leukemia
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials